GIPR and Obesity: However, co-administration augmented reductions in food intake, body weight and fat mass, and this was the rationale for the development of a unimolecular dual incretin receptor agonists (i.e., a single molecular structure with agonistic properties both at the GLP-1R and the GIPR) for the treatment of type 2 diabetes and obesity (this study will be discussed in more details below) [117].